3.9 Article

Combination Effects of Enalapril and Losartan on Lipid Peroxidation in the Kidneys of KK-A(y)/Ta Mice

Journal

NEPHRON EXPERIMENTAL NEPHROLOGY
Volume 113, Issue 2, Pages E66-E76

Publisher

KARGER
DOI: 10.1159/000228714

Keywords

Diabetic nephropathy; Lipid peroxidation; RAS inhibitor; AMPK; Adiponectin

Ask authors/readers for more resources

Background: Adenosine monophosphate activated protein kinase (AMPK) has a protective effect on lipid peroxidation. Adiponectin and AMPK might have a role in the pathogenesis of diabetic nephropathy. Blockade of the renin-angiotensin system (RAS) increases adiponectin levels and reduces oxidative stress. The objective of the present study was to examine lipid peroxidation via adiponectin and AMPK activation in the kidneys of KK-A(y)/Ta mice by RAS inhibitors, such as enalapril and/or losartan. Methods: KKA(y)/Ta mice were given enalapril (2.5 mg/kg/day) and/or losartan (25 mg/kg/day), or hydralazine (25 mg/kg/day) in the drinking water for 8 weeks starting at 8 weeks of age. They were divided into 5 groups as follows: enalapril 2.5 mg/kg/day treatment group (n = 5), losartan 25 mg/kg/day treatment group (n = 5), enalapril 2.5 mg/kg/day + losartan 25 mg/kg/day combination treatment group (n = 5), hydralazine 25 mg/kg/day treatment group (n = 5) and tap water group as the untreated group (n = 5). The urinary albumin/creatinine ratio (ACR), serum adiponectin and systemic blood pressure were measured as test parameters. Expressions of adiponectin, phospho-AMPK alpha (p-AMPK alpha) and phospho-acetyl CoA carboxylase(beta) (p-ACC(beta)) in the kidneys were evaluated by Western blot analyses. Pathological changes of glomeruli were evaluated by light microscopy. Accumulations of N-epsilon-(carboxymethyl) lysine (CML), malondialdehyde (MDA) and 4-hydroxy-2-nonenal (4-HNE) in glomeruli were evaluated by immunohistochemical analyses. Results: Enalapril and/or losartan improved levels of urinary ACR with activation of adiponectin, p-AMPK alpha and p-ACC(beta) in the kidneys. CML, MDA and 4-HNE expressions in glomeruli were significantly suppressed by enalapril and/or losartan, especially in the combination treatment group. Conclusions: It appears that enalapril and/or losartan, especially in combination, inhibited accumulation of CML/MDA/4-HNE in diabetic renal tissues. These effects might be related to lipid peroxidation via tissue-specific activation of adiponectin and AMPK. Copyright (C) 2009 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Endocrinology & Metabolism

Clinical predictive biomarkers for normoalbuminuric diabetic kidney disease

Tomohito Gohda, Yuji Nishizaki, Maki Murakoshi, Shuko Nojiri, Naotake Yanagisawa, Terumi Shibata, Mami Yamashita, Kanako Tanaka, Yoshinori Yamashita, Yusuke Suzuki, Nozomu Kamei

DIABETES RESEARCH AND CLINICAL PRACTICE (2018)

Article Multidisciplinary Sciences

Association between circulating tumor necrosis factor-related biomarkers and estimated glomerular filtration rate in type 2 diabetes

Nozomu Kamei, Mami Yamashita, Yuji Nishizaki, Naotake Yanagisawa, Shuko Nojiri, Kanako Tanaka, Yoshinori Yamashita, Terumi Shibata, Maki Murakoshi, Yusuke Suzuki, Tomohito Gohda

SCIENTIFIC REPORTS (2018)

Article Multidisciplinary Sciences

Chronic intermittent hypoxia-mediated renal sympathetic nerve activation in hypertension and cardiovascular disease

Keiko Takahashi, Seiji Ueda, Takashi Kobayashi, Akira Nishiyama, Yoshihide Fujisawa, Takeshi Sugaya, Satomi Shiota, Kazuhisa Takahashi, Tomohito Gohda, Satoshi Horikoshi, Yusuke Suzuki

SCIENTIFIC REPORTS (2018)

Article Endocrinology & Metabolism

Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease

Tomohito Gohda, Nozomu Kamei, Takeo Koshida, Mitsunobu Kubota, Kanako Tanaka, Yoshinori Yamashita, Eri Adachi, Saki Ichikawa, Maki Murakoshi, Seiji Ueda, Yusuke Suzuki

JOURNAL OF DIABETES INVESTIGATION (2020)

Review Biochemistry & Molecular Biology

Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease

Maki Murakoshi, Tomohito Gohda, Yusuke Suzuki

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Article Biochemistry & Molecular Biology

Aspartic acid supplementation ameliorates symptoms of diabetic kidney disease in mice

Saki Ichikawa, Tomohito Gohda, Maki Murakoshi, Li Zi, Eri Adachi, Takeo Koshida, Yusuke Suzuki

FEBS OPEN BIO (2020)

Article Endocrinology & Metabolism

Fractional excretion of tumor necrosis factor receptor 1 and 2 in patients with type 2 diabetes and normal renal function

Tomohito Gohda, Nozomu Kamei, Mitsunobu Kubota, Kanako Tanaka, Yoshinori Yamashita, Hiroko Sakuma, Chiaki Kishida, Eri Adachi, Takeo Koshida, Maki Murakoshi, Shinji Hagiwara, Kazuhiko Funabiki, Seiji Ueda, Yusuke Suzuki

Summary: Increased concentrations of serum TNFRs are positively associated with ACR and negatively associated with eGFR in patients with type 2 diabetes. The study shows that serum TNFRs are more strongly correlated with kidney measures, while urinary TNFRs are primarily associated with ACR.

JOURNAL OF DIABETES INVESTIGATION (2021)

Article Biochemistry & Molecular Biology

The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice

Zi Li, Maki Murakoshi, Saki Ichikawa, Takeo Koshida, Eri Adachi, Chigure Suzuki, Seiji Ueda, Tomohito Gohda, Yusuke Suzuki

FEBS OPEN BIO (2020)

Article Multidisciplinary Sciences

Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients

Tomohito Gohda, Maki Murakoshi, Yusuke Suzuki, Makoto Hiki, Toshio Naito, Kazuhisa Takahashi, Yoko Tabe

Summary: This study aimed to investigate the relationship between TNF-related biomarkers and mortality or disease severity in COVID-19 patients. The results showed that TNFR2 levels were associated with mortality in COVID-19 patients and may be helpful in predicting disease severity.

PLOS ONE (2022)

Review Biochemistry & Molecular Biology

Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials

Tomohito Gohda, Maki Murakoshi

Summary: Diabetic kidney disease (DKD) is a major cause of chronic kidney disease (CKD) and end-stage kidney disease. Early diagnosis, treatment, and risk factor management are important for preventing DKD progression. While current biomarkers for DKD diagnosis and prognosis are limited, measuring TNFRs in serum can help predict CKD prognosis. Cardiorenal risk factor management and certain medications are effective in slowing DKD progression, but there is still a high residual risk. Emerging therapies like SGLT2 inhibitors show promise for preventing DKD progression in patients with type 2 diabetes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Medicine, General & Internal

Development of an In-House EphA2 ELISA for Human Serum and Measurement of Circulating Levels of EphA2 in Hypertensive Patients with Renal Dysfunction

Maki Murakoshi, Takumi Iwasawa, Takeo Koshida, Yusuke Suzuki, Tomohito Gohda, Kazunori Kato

Summary: A novel ELISA method targeting EphA2 was validated and used to measure circulating EphA2 levels in hypertensive patients with kidney function decline, showing a potential application as a clinical biomarker for CKD presence.

DIAGNOSTICS (2022)

Article Biochemistry & Molecular Biology

Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease

Takeo Koshida, Tomohito Gohda, Takuya Sugimoto, Takashi Asahara, Rin Asao, Isao Ohsawa, Hiromichi Gotoh, Maki Murakoshi, Yusuke Suzuki, Yuichiro Yamashiro

Summary: The composition of the gut microbiome differs between patients with chronic kidney disease (CKD) undergoing hemodialysis (HD) and those with normal renal function (NRF). This difference is associated with altered levels of stool organic acids, systemic inflammation, and accumulation of uremic toxins (UTs). Furthermore, the levels of UTs, inflammatory markers, and stool organic acids differ significantly between patients with NRF and those undergoing HD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Urology & Nephrology

The proteinuria-lowering effects of dapagliflozin are associated with an initial decline in estimated glomerular filtration rate in patients with chronic kidney disease

Maki Murakoshi, Takashi Kobayashi, Masao Kihara, Seiji Ueda, Yusuke Suzuki, Tomohito Gohda

Summary: This study aimed to identify the clinical characteristics of patients with chronic kidney disease (CKD) who showed decreased proteinuria in response to dapagliflozin treatment. The results showed that the changes in urinary protein-to-creatinine ratio were positively associated with the initial decline rate in estimated glomerular filtration rate (eGFR) after 1 month of treatment.

NEPHROLOGY (2023)

Article Medicine, Research & Experimental

Effect of Zinc Acetate Dihydrate (Nobelzin®) Treatment on Anemia and Taste Disorders in Patients with Chronic Kidney Disease with Hypozincemia

Daisuke Sato, Tomohito Gohda, Masao Kihara, Yasuhiko Kanaguchi, Takashi Kobayashi, Satoshi Mano, Yu Sasaki, Nao Nohara, Maki Murakoshi, Junichiro Nakata, Hitoshi Suzuki, Seiji Ueda, Satoshi Horikoshi, Yusuke Suzuki

ACTA MEDICA OKAYAMA (2018)

Article Urology & Nephrology

Decline in estimated glomerular filtration rate is associated with risk of end-stage renal disease in type 2 diabetes with macroalbuminuria: an observational study from JDNCS

Miho Shimizu, Kengo Furuichi, Tadashi Toyama, Tomoaki Funamoto, Shinji Kitajima, Akinori Hara, Daisuke Ogawa, Daisuke Koya, Kenzo Ikeda, Yoshitaka Koshino, Yukie Kurokawa, Hideharu Abe, Kiyoshi Mori, Masaaki Nakayama, Yoshio Konishi, Ken-ichi Samejima, Masaru Matsui, Hiroyuki Yamauchi, Tomohito Gohda, Kei Fukami, Daisuke Nagata, Hidenori Yamazaki, Yukio Yuzawa, Yoshiki Suzuki, Shouichi Fujimoto, Shoichi Maruyama, Sawako Kato, Takero Naito, Kenichi Yoshimura, Hitoshi Yokoyama, Takashi Wada

CLINICAL AND EXPERIMENTAL NEPHROLOGY (2018)

No Data Available